GeneDx Holdings Corp.

Filing receipts

“Goodwill and Intangible Assets The change in the carrying amount of goodwill during the three months ended March 31, 2026 was as follows: Balance at December 31, 2025 $ 13,520 Impairment charges ( 11,879 ) Balance at March 31, 2026 $ 1,641 During the first quarter of 2026, the Company concluded that a triggering event had occurred during the period for the goodwill associated with the Fabric Genomics reporting unit primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.”

“For more information regarding our long-term debt, see Note 8, “ Long-term Debt .” Net cash provided by financing activities during the three months ended March 31, 2025 was $13.7 million, primarily driven by the $13.9 million net proceeds from our prior ATM offering, net of issuance costs.”

“Stock-Based Compensation Stock-based compensation expense is included within the condensed consolidated statements of operations and comprehensive loss as follows: Three months ended March 31, 2026 2025 Cost of services $ 380 $ 168 Research and development 1,406 419 Selling, general and administrative 7,210 3,396 Total stock-based compensation expense (1)(2) $ 8,996 $ 3,983 (1) The Company recorded an aggregate reversal of stock-based compensation of $ 0.8 million and $ 0.6 million during the three months ended March 31, 2026 and 2025, respectively, due to forfeiture activities upon employee terminations. (2) Includes $ 1.1 million and $ 0.3 million of expenses related to the 2021 Employee...”